Sarcoidosis is a chronic inflammatory disorder of unclear aetiology, affecting mainly lungs and skin. Its clinical course can range from an acute selflimiting process to a chronic progressive disease with significant morbidity and mortality.1 Increasingly, data shows that sarcoidosis may be a hypercoagulable state and a potent risk factor for venous thromboembolism (VTE), as several autoimmune disorders.2,3 Furthermore, its treatment can be challenging and occasionally it can be associated with rare adverse events, such as pulmonary hypertension.4

Since the outbreak of COVID-19 pandemic, COVID-19 infection, apart from causing severe, often fatal pneumonia, seems to have been associated with coagulation abnormalities, such as raised procoagulant factors, and with higher mortality.5,6

During the pandemic, Sarcoidosis UK has reported that sarcoidosis patients have shown significantly higher levels of cardiac involvement than previously thought. Therefore, an urgent review of any sarcoidosis patient’s cardiac and lung function and treatment amendment should be requested.7

DOWNLOAD THE PDF TO READ THE FULL ARTICLE